Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 7, 2010, Pages 2910-2919

  Larrouy, Lucile ^a,b   Chazallon, C ^c   Landman, R ^a,b   Capitant, C ^c   Peytavin, G ^a,b   Collin, G ^a,b   Charpentier, C ^a,b   Storto, A ^a,b   Pialoux, G ^d,e   Katlama, C ^c,d,f   Girard, P M ^d,g   Yeni, P ^a,b   Aboulker, J P ^c   Brun Vezinet, F ^a,b   Descamps, D ^a,b  

^a BICHAT HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HÔPITAL TENON   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; POL PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; VIRUS RNA; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT RESPONSE; AMINO ACID SEQUENCE; CLASSIFICATION; CONTROLLED STUDY; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR GENETICS; MULTIVARIATE ANALYSIS; MUTATION; PHYLOGENY; RANDOMIZED CONTROLLED TRIAL; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MULTIVARIATE ANALYSIS; MUTATION; PHYLOGENY; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 77953789703     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00194-10     Document Type: Article

References (56)

1. Bally, F., R. Martinez, S. Peters, P. Sudre, and A. Telenti. 2000. Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res. Hum. Retroviruses 16:1209-1213.
2. Banke, S., M. R. Lillemark, J. Gerstoft, N. Obel, and L. B. Jorgensen. 2009. Positive selection pressure introduces secondary mutations at Gag cleavage sites in human immunodeficiency virus type 1 harboring major protease resistance mutations. J. Virol. 83:8916-8924.
3. Baril, M., D. Dulude, K. Gendron, G. Lemay, and L. Brakier-Gingras. 2003. Efficiency of a programmed -1 ribosomal frameshift in the different subtypes of the human immunodeficiency virus type 1 group M. RNA 9:1246-1253. (Pubitemid 37151678)
4. Callebaut, C. S., K. Stray, L. Tsai, L. Xu, W. Lee, and T. Cihlar. 2007. In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir. XVIth Int. HIV Drug Resist. Workshop, abstr. 16.
5. Carrillo, A., K. D. Stewart, H. L. Sham, D. W. Norbeck, W. E. Kohlbrenner, J. M. Leonard, D. J. Kempf, and A. Molla. 1998. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72:7532-7541.
6. Chang, S. Y., R. Sutthent, P. Auewarakul, C. Apichartpiyakul, M. Essex, and T. H. Lee. 1999. Differential stability of the mRNA secondary structures in the frameshift site of various HIV type 1 viruses. AIDS Res. Hum. Retroviruses 15:1591-1596.
7. Coren, L. V., J. A. Thomas, E. Chertova, R. C. Sowder, T. D. Gagliardi, R. J. Gorelick, and D. E. Ott. 2007. Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1. J. Virol. 81:10047-10054.
8. Côté, H. C., Z. L. Brumme, and P. R. Harrigan. 2001. Human immunode-ficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J. Virol. 75:589-594.
9. Dam, E., R. Quercia, B. Glass, D. Descamps, O. Launay, X. Duval, H. Kräusslich, A. J. Hance, and F. Clavel. 2009. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog. 5:e1000345.
10. Dinman, J. D., S. Richter, E. P. Plant, R. C. Taylor, A. B. Hammell, and T. M. Rana. 2002. The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure. Proc. Natl. Acad. Sci. U. S. A. 99:5331-5336.
11. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 70:3763-3769. (Pubitemid 26161824)
12. Doyon, L., C. Payant, L. Brakier-Gingras, and D. Lamarre. 1998. Novel Gag-Pol frameshift site in human immunodeficiency virus type 1 variants resistant to protease inhibitors. J. Virol. 72:6146-6150. (Pubitemid 28283405)
13. Dulude, D., M. Baril, and L. Brakier-Gingras. 2002. Characterization of the frameshift stimulatory signal controlling a programmed -1 ribosomal frame-shift in the human immunodeficiency virus type 1. Nucleic Acids Res. 30:5094-5102.
14. Fehér, A., I. T. Weber, P. Bagossi, P. Boross, B. Mahalingam, J. M. Louis, T. D. Copeland, I. Y. Torshin, R. W. Harrison, and J. Tözsér. 2002. Effect of sequence polymorphism and drug resistance on two HIV-1 Gag processing sites. Eur. J. Biochem. 269:4114-4120.
15. Felsenstein, K. M., and S. P. Goff. 1988. Expression of the gag-pol fusion protein of Moloney murine leukemia virus without gag protein does not induce virion formation or proteolytic processing. J. Virol. 62:2179-2182.
16. Gallego, O., C. de Mendoza, A. Corral, and V. Soriano. 2003. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J. Clin. Microbiol. 41:1245-1247.
17. Garcia-Diaz, A., A. Fox, U. B. Dragsted, J. Kjaer, N. Clumeck, A. Philips, J. D. Lundgren, and A. M. Geretti. 2008. Treatment-emergent gag cleavage site mutations during virological failure of ritonavir-boosted protease inhibitors. XVIIth Int. HIV Drug Resist. Workshop, abstr. 73.
18. Gathe, J. C., P. Ive, R. Wood, D. Schürmann, N. C. Bellos, E. DeJesus, A. Gladysz, C. Garris, and J. Yeo. 2004. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfi-navir in naive HIV-1-infected patients. AIDS 18:1529-1537.
19. Ghosn, J., C. Delaugerre, P. Flandre, J. Galimard, F. Raffi, M. Norton, J. F. Delfraissy, C. Rouzioux, and M. L. Chaix. 2009. Sixteenth Conf. Retrovir. Oppor. Infect., Montreal, Canada, abstr. 630.
20. Girnary, R., L. King, L. Robinson, R. Elston, and I. Brierley. 2007. Structurefunction analysis of the ribosomal frameshifting signal of two human immunodeficiency virus type 1 isolates with increased resistance to viral protease inhibitors. J. Gen. Virol. 88:226-235.
21. Gonzalez-Garcia, J., A. J. Carcas-Sansuan, B. Duque, J. R. Arribas, A. Soto, J. M. Pena, and J. Frias-Iniesta. 2002. XIVth Int. AIDS Conf., Barcelona, Spain, abstr. B10398.
22. Ho, S. K., R. M. Coman, J. C. Bunger, S. L. Rose, P. O'Brien, I. Munoz, B. M. Dunn, J. W. Sleasman, and M. M. Goodenow. 2008. Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology 378:272-281.
23. Jinnopat, P., P. Isarangkura-na-ayuthaya, P. Utachee, Y. Kitagawa, U. C. de Silva, U. Siripanyaphinyo, Y. Kameoka, K. Tokunaga, P. Sawanpanyalert, K. Ikuta, W. Auwanit, and M. Kameoka. 2009. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01-AE strains on drug susceptibility of virus to protease inhibitors. J. Acquir. Immune Defic. Syndr. 52:320-328.
24. Karacostas, V., E. J. Wolffe, K. Nagashima, M. A. Gonda, and B. Moss. 1993. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 193:661-671.
25. Kaufmann, G. R., K. Suzuki, P. Cunningham, M. Mukaide, M. Kondo, M. Imai, J. Zaunders, and D. A. Cooper. 2001. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res. Hum. Retroviruses 17:487-497.
26. Kempf, D. J., M. S. King, B. Bernstein, P. Cernohous, E. Bauer, J. Moseley, K. Gu, A. Hsu, S. Brun, and E. Sun. 2004. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis. 189:51-60.
27. Knops, E., G. Théberge-Julien, R. Kaiser, D. Hoffman, L. Brakier-Gingras, and J. Verheyen. 2009. Differences in the frameshift-regulating p1-site in treatment-naive and PI-resistant HIV isolates. XVIIIth Int. HIV Drug Resist. Workshop, abstr. 99.
28. Kolli, M., and C. A. Schiffer. 2009. Insights into the mechanism of resistancecoevolution of the nelfinavir-resistant HIV-1 protease and the p1-p6 cleavage site. XVIIIth Int. HIV Drug Resist. Workshop, abstr. 98.
29. Kolli, M., S. Lastere, and C. A. Schiffer. 2006. Co-evolution of nelfinavirresistant HIV-1 protease and the p1-p6 substrate. Virology 347:405-409.
30. Kolli, M., E. Stawiski, C. Chappey, and C. A. Schiffer. 2009. Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance. J. Virol. 83:11027-11042.
31. Lambert-Niclot, S., P. Flandre, I. Malet, A. Canestri, C. Soulié, R. Tubiana, C. Brunet, M. Wirden, C. Katlama, V. Calvez, and A. Marcelin. 2008. Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease. J. Antimicrob. Chemother. 62:905-908.
32. Landman, R., C. Capitant, D. Descamps, C. Chazallon, G. Peytavin, C. Katlama, G. Pialoux, M. Bentata, F. Brun-Vézinet, J. Aboulker, and P. Yéni. 2009. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study. J. Antimicrob. Chemother. 64:118-125.
33. Larrouy, L., C. Chazallon, R. Landman, C. Capitant, G. Peytavin, P. M. Girard, P. Yéni, J. P. Aboulker, F. Brun-Vézinet, and D. Descamps on behalf of the ANRS 127 Study Group. 2009. Influence of gag genetic determinants on virological response to dual boosted protease inhibitor combinations in ART-naïve patients: ANRS 127 trial, abstr. 631. Sixteenth Conf. Retrovir. Oppor. Infect., Montréal, Canada.
34. Larrouy, L., C. Chazallon, R. Landman, C. Capitant, G. Collin, A. Storto, G. Peytavin, G. Pialoux, C. Katlama, P. M. Girard, P. Yeni, J. P. Aboulker, F. Brun-Vezinet, and D. Descamps on behalf of the ANRS 127 Study Group. 2009. Impact of Gag genetic determinants and gag-pol frameshift stability on virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve patients (ANRS 127 trial), abstr. 57. Antivir. Ther., Fort Myers, FL.
35. Ludwig, C., A. Leiherer, and R. Wagner. 2008. Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation. J. Virol. 82:4573-4584.
36. Maguire, M. F., R. Guinea, P. Griffin, S. Macmanus, R. C. Elston, J. Wolfram, N. Richards, M. H. Hanlon, D. J. T. Porter, T. Wrin, N. Parkin, M. Tisdale, E. Furfine, C. Petropoulos, B. W. Snowden, and J. Kleim. 2002. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J. Virol. 76:7398-7406.
37. Malet, I., B. Roquebert, C. Dalban, M. Wirden, B. Amellal, R. Agher, A. Simon, C. Katlama, D. Costagliola, V. Calvez, and A. Marcelin. 2007. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients. J. Infect. 54:367-374.
38. Mammano, F., C. Petit, and F. Clavel. 1998. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72:7632-7637. (Pubitemid 28377901)
39. Nijhuis, M., N. M. van Maarseveen, S. Lastere, P. Schipper, E. Coakley, B. Glass, M. Rovenska, D. de Jong, C. Chappey, I. W. Goedegebuure, G. Heilek-Snyder, D. Dulude, N. Cammack, L. Brakier-Gingras, J. Konvalinka, N. Parkin, H. Kräusslich, F. Brun-Vezinet, and C. A. B. Boucher. 2007. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med. 4:e36.
40. Park, J., and C. D. Morrow. 1991. Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J. Virol. 65:5111-5117.
41. Parkin, N. T., M. Chamorro, and H. E. Varmus. 1992. Human immunode-ficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo. J. Virol. 66:5147-5151.
42. Parry, C. M., A. Kohli, C. J. Boinett, G. J. Towers, A. L. McCormick, and D. Pillay. 2009. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J. Virol. 83:9094-9101.
43. Pettit, S. C., M. D. Moody, R. S. Wehbie, A. H. Kaplan, P. V. Nantermet, C. A. Klein, and R. Swanstrom. 1994. The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68:8017-8027.
44. Pettit, S. C., G. J. Henderson, C. A. Schiffer, and R. Swanstrom. 2002. Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J. Virol. 76:10226-10233.
45. Prabu-Jeyabalan, M., E. A. Nalivaika, N. M. King, and C. A. Schiffer. 2004. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J. Virol. 78:12446-12454.
46. Prado, J. G., T. Wrin, J. Beauchaine, L. Ruiz, C. J. Petropoulos, S. D. W. Frost, B. Clotet, R. T. D'Aquila, and J. Martinez-Picado. 2002. Amprenavirresistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS 16:1009-1017.
47. Staszewski, S., E. Babacan, C. Stephan, A. Haberl, A. Carlebach, P. Gute, S. Klauke, Y. Hermschulte, M. Stuermer, and B. Dauer. 2006. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J. Antimicrob. Chemother. 58:1024-1030.
48. Telenti, A., R. Martinez, M. Munoz, G. Bleiber, G. Greub, D. Sanglard, and S. Peters. 2002. Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure. J. Virol. 76:7868-7873.
49. Ulbricht, K., M. Stoll, G. Behrens, B. Salzberger, H. Jessen, A. Jessen, B. Kuhlmann, A. Trein, H. Heiken, and R. Schmidt. 2008. Fifteenth Conf. Retrovir. Oppor. Infect., Boston, MA, abstr. 780.
50. Verheyen J., A. Altmann, E. Knops, E. Schülter, N. Sichtig, S. Reuter, G. Fätkenheuer, H. Pfister, and R. Kaiser. 2008. Relevance of HIV gag cleavage site mutations in failures of protease inhibitor therapies. XVIIth Int. HIV Drug Resist. Workshop, abstr. 48.
51. Verheyen, J., E. Knops, B. Kupfer, O. Hamouda, S. Somogyi, U. Schuldenzucker, D. Hoffmann, R. Kaiser, H. Pfister, and C. Kücherer. 2009. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients. J. Infect. 58:61-67.
52. Verheyen, J. K., E. Knops, E. Schülter, N. Sichtig, S. Reuter, G. Fätkentheuer, J. K. Rockstroh, U. Schuldenzucker, D. Hofmann, H. Pfister, and R. Kaiser. 2008. Sixth Eur. HIV Drug Resist. Workshop, Budapest, Hungary, abstr. 45.
53. Verheyen, J., E. Litau, T. Sing, M. Däumer, M. Balduin, M. Oette, G. Fätkenheuer, J. K. Rockstroh, U. Schuldenzucker, D. Hoffmann, H. Pfister, and R. Kaiser. 2006. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antivir. Ther. 11:879-887.
54. Yates, P. J., R. Hazen, M. St. Clair, L. Boone, M. Tisdale, and R. C. Elston. 2006. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385. Antimicrob. Agents Chemother. 50:1092-1095.
55. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306. (Pubitemid 28175575)
56. Zhang, Y. M., H. Imamichi, T. Imamichi, H. C. Lane, J. Falloon, M. B. Vasudevachari, and N. P. Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.